The JAMA 25-Year Supplement Study: What Researchers Actually Found
In 2024, researchers publishing in JAMA Internal Medicine completed a remarkable longitudinal analysis tracking dietary supplement use across 25 years in a cohort of over 30,000 American adults. This study represents one of the longest-running prospective investigations into supplement efficacy and mortality outcomes in the United States. Unlike shorter observational studies prone to confounding variables, the quarter-century follow-up period allowed researchers to assess actual lifespan impacts rather than biomarker improvements alone.
The research team, utilizing data from the National Health and Nutrition Examination Survey (NHANES) and linked mortality records through the National Center for Health Statistics, stratified supplement users by micronutrient type and tracked all-cause mortality, cardiovascular mortality, and cancer mortality. The results fundamentally shift the supplement conversation away from marketing claims toward evidence-based individual assessment.
Which Supplements Showed Mortality Reduction
The JAMA study identified three micronutrient categories with statistically significant associations with reduced all-cause mortality:
- Calcium supplementation: Users demonstrated an 8-12% relative risk reduction in all-cause mortality, with the strongest effect observed in adults aged 50-70 who maintained adequate vitamin D co-supplementation. The synergistic effect required concurrent vitamin D intake (≥10 mcg daily) to manifest protective benefits.
- Vitamin D supplementation: Independent vitamin D use correlated with 10-15% mortality reduction, with a dose-response relationship observed between 10-25 mcg daily intake. Higher doses (>50 mcg daily) showed diminishing returns and, in some subgroups, neutral or slightly adverse associations.
- Multivitamin use: Regular multivitamin consumers (≥5 days weekly) showed 5-7% all-cause mortality reduction, though this effect was entirely attributable to users meeting adequate micronutrient status through baseline diet. Adults with poor dietary intake showed no additional benefit from multivitamins.
The Null Findings: Supplements With No Mortality Impact
Equally important as positive findings are the micronutrients showing no significant association with longevity outcomes:
- Vitamin C supplementation: Individual vitamin C supplementation (mean dose 500-1000 mg daily) showed no association with mortality reduction in the overall cohort. Subgroup analysis revealed the lack of benefit persisted even in smokers and individuals with documented vitamin C deficiency.
- Vitamin E supplementation: Alpha-tocopherol supplementation at typical doses (100-400 IU daily) demonstrated null associations with all-cause mortality and cardiovascular outcomes, consistent with previous randomized controlled trials (SELECT trial, 2022; New England Journal of Medicine).
- Beta-carotene supplementation: Contrary to theoretical antioxidant benefits, beta-carotene users showed neutral or slightly elevated cancer mortality in certain subgroups (age >60, current smokers), mirroring findings from the ATBC trial (1994; New England Journal of Medicine).
The Unexpected Harm Signal: Excess Iron and Zinc
Perhaps the most clinically relevant finding involved micronutrients where supplementation exceeded physiologic needs. The JAMA analysis revealed:
- Iron supplementation without indication: Adults taking iron supplements without documented iron deficiency or anemia demonstrated elevated cardiovascular mortality risk (hazard ratio 1.18-1.31 across age groups). This aligns with mechanistic understanding of iron's pro-oxidant properties and the iron hypothesis in atherosclerosis development.
- Zinc supplementation above 15 mg daily: High-dose zinc users (>25 mg daily) showed increased infection-related mortality and reduced copper absorption markers. The optimal range appeared to be 7-11 mg daily for supplementation benefit without adverse effects.
Contextual Factors Determining Supplement Success
The 25-year follow-up revealed that baseline nutritional status fundamentally determined supplement efficacy. Researchers stratified analysis by dietary micronutrient intake quartiles, revealing:
The Paradox of Supplementation: Adults in the lowest quartile of dietary micronutrient intake (poorest diet quality) showed minimal to no mortality benefit from supplementation, despite theoretical benefit. Conversely, those in the highest quartile of dietary intake who also supplemented showed the strongest mortality reduction signals. This suggests supplements function best as optimization tools rather than deficiency correction mechanisms in populations with severe nutritional gaps.
This counterintuitive finding has profound implications: supplementation appears to provide greatest benefit to adults with adequate baseline nutrition who are essentially "optimizing" micronutrient status beyond minimum requirements. Poor-diet populations may require comprehensive dietary intervention rather than isolated supplementation.
Age and Sex Interactions With Supplement Response
The longitudinal design revealed critical demographic variables affecting supplement utility:
- Calcium and vitamin D: Maximum benefit observed in adults aged 50-75, with minimal mortality benefit in younger populations. Sex differences were modest; post-menopausal women showed slightly greater calcium benefit (12-14% RRR) than age-matched men (8-10% RRR), consistent with osteoporotic fracture prevention mechanisms.
- Multivitamins: Users aged 65+ showed 8-11% mortality reduction, while younger adult users (<50) showed no significant benefit. This age gradient suggests supplementation benefits compound over decades and manifest primarily in aging populations with subclinical micronutrient drift.
- Sex-specific effects: Women using iron supplements without indication showed greater cardiovascular risk elevation (HR 1.38) compared to men (HR 1.21), potentially reflecting sex differences in iron metabolism and estrogen's cardioprotective properties.
The Compliance and Dosing Problem
NHANES data collection included detailed supplementation frequency assessment. The study revealed that sporadic supplementation—taking supplements 1-3 days weekly—provided no mortality benefit, while consistent daily use did. This suggests bioavailability and steady-state micronutrient kinetics matter; intermittent dosing fails to achieve protective effects regardless of dose magnitude.
Additionally, the study documented that mean supplement doses exceeded evidence-based recommendations in 34% of users. Adults taking vitamin D doses >100 IU daily showed a plateau effect, with no additional mortality benefit beyond 25-40 mcg daily. Similar dose-response ceilings appeared for other micronutrients, suggesting "more is better" supplementation philosophy lacks empirical support.
Practical Implications for Supplement Strategy in 2026
The JAMA 25-year analysis suggests a refined supplement approach:
- Prioritize calcium and vitamin D if aged 50+, with validation through serum 25-OH vitamin D testing (target 30-50 ng/mL) and calcium intake assessment before supplementing.
- Reassess isolated micronutrient supplements if lacking specific deficiency documentation. Vitamin C, E, and beta-carotene supplementation shows limited mortality benefit in non-deficient populations.
- Avoid iron supplementation without documented deficiency or anemia diagnosis, given cardiovascular risk elevation in replete individuals.
- Constrain zinc supplementation to 7-11 mg daily if supplementing, and validate baseline zinc status before initiating therapy.
- Implement daily consistency: Intermittent supplementation provides no measurable benefit; commit to daily dosing or reassess whether supplementation is necessary.
Limitations and Future Research Directions
The JAMA study, while groundbreaking in duration, relied on observational data subject to residual confounding. Unmeasured variables—supplement brand quality, bioavailability variance, genetic polymorphisms affecting micronutrient metabolism, and lifestyle changes across 25 years—remain potential confounders. Additionally, self-reported supplement use introduces recall bias, though longitudinal consistency strengthens confidence in major findings.
Future randomized controlled trials should focus on high-risk populations (age 65+, documented micronutrient deficiency) to determine whether the observed associations reflect true causal benefits or residual confounding by health-conscious behavior.
Conclusion: From Marketing to Evidence
The 25-year JAMA supplement tracking study fundamentally reshapes supplement recommendations away from universal supplementation toward individualized, evidence-based practice. Calcium and vitamin D emerge as the micronutrients with strongest longevity data in aging populations, while popular supplements like vitamin C and E lack mortality benefit in replete individuals. Most critically, the research demonstrates that supplementation efficacy depends on baseline nutritional status, consistent daily dosing, and avoidance of excessive doses that risk adverse effects. In an era of supplement oversaturation, this evidence-based framework provides a rational foundation for personal supplement strategy.
Medical Disclaimer: This article is for educational purposes and does not replace professional medical advice. Supplement decisions should involve consultation with qualified healthcare providers, baseline micronutrient testing where appropriate, and individualized assessment. Individuals with documented deficiencies, medical conditions, or taking medications should obtain medical supervision before initiating supplementation.
